160 related articles for article (PubMed ID: 33621330)
21. [Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer].
Szarvas T; Csizmarik A; Nagy N; Keresztes D; Váradi M; Küronya Z; Riesz P; Nyirády P
Orv Hetil; 2020 May; 161(20):813-820. PubMed ID: 32364360
[TBL] [Abstract][Full Text] [Related]
22. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
23. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Davies RS; Smith C; Lester JF
Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
[TBL] [Abstract][Full Text] [Related]
24. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
25. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Oh WK; Cheng WY; Miao R; Vekeman F; Gauthier-Loiselle M; Duh MS; Drea E; Szatrowski TP
Urol Oncol; 2018 Nov; 36(11):500.e1-500.e9. PubMed ID: 30201382
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Shiota M; Blas L; Kobayashi S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Int J Urol; 2022 Jan; 29(1):26-32. PubMed ID: 34549837
[TBL] [Abstract][Full Text] [Related]
27. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
De Laere B; Rajan P; Grönberg H; Dirix L; Lindberg J;
JAMA Oncol; 2019 Jul; 5(7):1060-1062. PubMed ID: 31046065
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases.
Oruç Z; Kaplan MA; Karaağaç M; Özyurt N; Tatlı AM; Kaya AO; Menekşe S; Kut E; Koca S; Sever ÖN; Yasin İ; Ebinç S; Zeynelgil E; Sakin A; Turhal NS; Isikdogan A
Future Oncol; 2021 May; 17(13):1611-1624. PubMed ID: 33631986
[TBL] [Abstract][Full Text] [Related]
29. Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.
Fukuokaya W; Kimura T; Urabe F; Kimura S; Tashiro K; Tsuzuki S; Koike Y; Sasaki H; Miki K; Egawa S
Int J Clin Oncol; 2020 Sep; 25(9):1695-1703. PubMed ID: 32488548
[TBL] [Abstract][Full Text] [Related]
30. Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
Robinson AG; Izard JP; Vera-Badillo FE
Eur Urol; 2021 Aug; 80(2):123-126. PubMed ID: 33773874
[TBL] [Abstract][Full Text] [Related]
31. Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
Ternov KK; Nolsøe AB; Bratt O; Fode M; Lindberg H; Kistorp C; Palapattu G; Klausen TW; Sønksen J; Østergren PB
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):948-961. PubMed ID: 33820951
[TBL] [Abstract][Full Text] [Related]
32. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
34. The evolving options in metastatic castration-sensitive prostate cancer.
Hamilou Z
Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
37. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
[TBL] [Abstract][Full Text] [Related]
38. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
Lee HY; Chen HL; Teoh JY; Chen TC; Hao SY; Tsai HY; Huang WH; Juan YS; Cheng HM; Chang HM
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):244-252. PubMed ID: 32860011
[TBL] [Abstract][Full Text] [Related]
39. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
40. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
